Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$1,000.79 USD
-5.08 (-0.51%)
Updated Jun 6, 2024 04:00 PM ET
After-Market: $1,001.51 +0.72 (0.07%) 6:26 PM ET
3-Hold of 5 3
C Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
REGN 1,000.79 -5.08(-0.51%)
Will REGN be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for REGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for REGN
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
Health Care Stocks Show Relative Strength as S&P 500 Stalls
REGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
Should You Invest in the iShares Biotechnology ETF (IBB)?
J&J (JNJ) to Buy Rights to Novel Atopic Dermatitis Candidate
Other News for REGN
FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward
Biotech Alert: Searches spiking for these stocks today
Goldman cuts 2seventy bio to neutral, cites competition concerns
ASCO 2024 Round-Up: Some Of The Most Impactful Cancer News Out Of The Big Meeting
Regeneron Pharmaceuticals, Inc. (REGN) Management presents at Jefferies 2024 Global Healthcare Conference (Transcript)